Aurodox is a polyketide antibiotic originally isolated from S. goldiniensis. [1] It is active against Gram-positive bacteria, including B. megaterium, B. anthracis, and M. hominis (MICs = 0.06, 0.6, and 3-10 µg/ml, respectively), as well as Pneumococcus and Streptomyces species (MICs = 3-12 and 3-30 µg/ml, respectively). It is effective against S. pyogenes infection in mice with a 50% curative dose (CD50) value of 71 mg/kg. Aurodox inhibits bacterial protein synthesis by binding to bacterial elongation factor Tu (EF-Tu) and inhibiting its release from the ribosome. [2][3]
Reference:
[1]. Berger, J., Lehr, H.A., Teitel, S., et al. A new antibiotic X-5108 OF Streptomyces origin. I. Production, isolation and properties. J. Antibiot. (Tokyo) 26(1), 15-22 (1973).
[2]. Wolf, H., Chinali, G., and Parmeggiani, A. Mechanism of the inhibition of protein synthesis by kirromycin. Role of elongation factor Tu and ribosomes. Eur. J. Biochem. 75(1), 67-75 (1977).
[3]. Bhuta, P., and Chládek, S. Stimulation of Escherichia coli elongation factor Tu-dependent GTP hydrolysis by aminoacyl oligonucleotides in the presence of aurodox. FEBS Lett. 122(1), 113-116 (1980).